Skip to content

Unrealized gains at other companies

Kulicke & Soffa Industries logo
Kulicke & Soffa IndustriesKLIC
$0
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$73K+82.5%
Nuvation Bio logo
Nuvation BioNUVB
$797K+33.7%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$88K
The Bancorp logo
The BancorpTBBK
$20.61M+29.6%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$88K

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept tars:CashAndCashEquivalentsAccumulatedUnrealizedGainsBeforeTax.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s unrealized gains.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s unrealized gains?
Tarsus Pharmaceuticals, Inc. (TARS) reported unrealized gains of $1K in Q4 2025.
What does unrealized gains mean?
The cumulative unrealized gains associated with cash equivalents or short-term liquid investments held by the company. This reflects the mark-to-market performance of the company's liquid treasury assets prior to any actual sale or realization.